CX3CL1
Fractalkine
As of the edition of 20 October 2026, CX3CL1 (fractalkine, UniProt P78423) has 1 drug tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P78423
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 15
- Disease areas
- Digestive system; Bones, joints and muscles; Immune system; Skin and connective tissue
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Quetmolimab | Stopped | Phase 2 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
The other 0 companies at CX3CL1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at CX3CL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.